Distribution of low risk DIN/NPN products as samples

Distribution of low risk DIN/NPN products as samples

Published on May 4, 2020

Author: Teri Dickinson, Manager, Regulatory Affairs, Dell Tech Laboratories Ltd.

Beginning July 1, 2020, industry will be able to distribute certain non-prescription drugs and NHPs as samples as a strategy to encourage their use on a trial basis. This may provide benefits to Canadians, practitioners and pharmacists by increasing their knowledge of available health product options to meet their needs.

Amendments to the Food and Drug Regulations following the ratification of the Canada-United States-Mexico Agreement, now permit the distribution of specific low risk non-prescription drugs and natural health products as samples under certain conditions.  Section 14 of the Food and Drugs Act previously prohibited the distribution of drugs as samples other than to physicians, dentists, veterinary surgeons or pharmacists, under prescribed conditions.

To assist stakeholders with interpreting the legislative and regulatory requirements associated with distributing these samples, Health Canada prepared a new guidance document entitled “Distributing samples of prescription drugs, non-prescription drugs and natural health products”.

Some of the low risk DIN and NPN products that can be distributed directly to consumers include:

  • Personal Care Use Antiseptic Cleansers
  • Sunscreens
  • Acne Therapy Products

References:

Regulations Amending the Food and Drug Regulations (Distribution of Drugs as Samples): SOR/2020-74 - http://www.gazette.gc.ca/rp-pr/p2/2020/2020-04-29/html/sor-dors74-eng.html

Guidance Document on the Distribution of Drugs as Samples - Summary - https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/legislation-guidelines/guidance-documents/distribution-drugs-samples-summary.html

Related Articles

Health Canada’s Proposal for Clinical Trials Regulatory Modernization

Health Canada’s Proposal for Clinical Trials Regulatory Modernization

On May 20, 2021 Health Canada opened a consultation on its proposal to modernize the regulatory framework for clinical trials related to human drugs, medical devices,...

Interim Order No. 2 Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19

Interim Order No. 2 Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19

In response to the ongoing need for innovative COVID-19 diagnosis, treatment, mitigation, or prevention options, Health Canada announced the approval of Interim Order No. 2...